In Brief: Sequus
Executive Summary
Sequus: Final chemistry issue regarding the approval of Doxil liposomal doxorubicin is resolved with FDA Nov. 7, Sequus President Scott Minick tells an Oppenheimer & Co. conference Nov. 8. Doxil labeling for treatment of refractory Kaposi's sarcoma will state that 27%-48% of patients responded to the compound and that Doxil selectively enters KS lesions, leading to greater tumor concentration of doxorubicin than with non-liposomal formulations. Doxil will be priced similarly to Bristol-Myers Squibb's Taxol, Minick said. The Menlo Park, Calif.-based company is ready to launch Doxil immediately upon approval, he added...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth